Bionano Genomics (NASDAQ:BNGO) Announces Quarterly Earnings Results

Bionano Genomics (NASDAQ:BNGO) released its earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.09), FiscalAI reports. The business had revenue of $8.28 million for the quarter, compared to analysts’ expectations of $8.44 million. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 78.78%.

Here are the key takeaways from Bionano Genomics’ conference call:

• Usage and recurring consumables grew: Q3 revenue rose 12% year over year to $8.3 million, while flow-cell sales reached a quarterly record of 9,870, up 18%. Consumable revenue increased 24%, although software revenue fell 31% on fewer VIA licenses.
• Profitability metrics improved: Adjusted gross margin rose to 48% from 46% a year earlier, and adjusted operating expenses declined 9% to $8.8 million. Management said it expects to reach adjusted EBITDA neutrality by the end of 2027.
• 2026 guidance was reaffirmed: Bionano expects full-year revenue of $31 million to $33 million, representing 9%–16% growth, and said it expects to land near the midpoint. Management described its previously discussed 2027 revenue range as a vision rather than confirmed guidance.
• Clinical adoption and reimbursement support advanced: MolDx proposed Medicare coverage for OGM testing in hematologic cancers across jurisdictions representing 31 states, with a final determination still pending. New York approvals at University of Rochester Medicine and Memorial Sloan Kettering, along with new clinical studies, add to adoption evidence.
• Supply constraints are limiting near-term sales: Long lead times for critical components have kept Bionano from meeting strong customer demand. Management expects backorders to clear by year-end and plans to roughly double capacity by mid-2027, but those timelines remain forward-looking.

Bionano Genomics Stock Down 7.3%

BNGO stock traded down $0.09 during mid-day trading on Wednesday, hitting $1.14. The stock had a trading volume of 268,254 shares, compared to its average volume of 441,505. Bionano Genomics has a 1-year low of $1.00 and a 1-year high of $2.23. The company has a fifty day moving average of $1.37 and a 200 day moving average of $1.23. The company has a current ratio of 2.48, a quick ratio of 1.96 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $15.94 million, a price-to-earnings ratio of -0.38 and a beta of 1.73.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings raised shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a research note on Saturday, September 26th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.00.

Bionano Genomics Company Profile

Bionano Genomics, Inc. is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations. The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.